Home › RLT targets by cancer › Gastric Cancer
Radioligand therapy · Gastric Cancer

Radioligand Therapy Targets in Gastric Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in gastric cancer (including stomach adenocarcinoma). 4,271 show detectable protein staining. Established and emerging radioligand targets expressed in gastric cancer include HER3 (ERBB3), CEA (CEACAM5), FAP and c-MET (MET). Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own gastric cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank gastric cancer targets free

Established and emerging radioligand targets in gastric cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in gastric cancer:

TargetIHC in gastric cancer% positiveInternalizes
HER3 (ERBB3)High (0.93)100%yes
CEA (CEACAM5)High (0.73)91%—
FAPHigh (0.70)100%yes
c-MET (MET)High (0.64)100%yes
STEAP2High (0.64)100%—
B7-H3 (CD276)High (0.53)100%—
SSTR2Medium (0.50)83%yes
Claudin 18.2 (CLDN18)Medium (0.44)50%uncertain
ITGAVMedium (0.39)67%—
EGFRMedium (0.36)73%yes
Mesothelin (MSLN)Medium (0.33)50%yes
TMEFF2Medium (0.30)55%—
CAIX (CA9)Medium (0.21)36%no
EPCAMLow (0.17)30%—
HER2 (ERBB2)Low (0.11)17%yes
ITGB6Low (0.10)20%—
Nectin-4 (NECTIN4)Low (0.07)20%no
PSCALow (0.06)8%—
STEAP1Low (0.03)10%—

Top cell-surface targets for gastric cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in gastric cancer% positiveInternalizesClinical stage
1HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.93)100%yesFDA-Approved
2IGF1R
insulin like growth factor 1 receptor
High (0.86)100%yesFDA-Approved
3c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
High (0.64)100%yesFDA-Approved
4CYSLTR2
cysteinyl leukotriene receptor 2
High (0.86)92%yesDiscovery
5AMFR
autocrine motility factor receptor
High (1.00)100%yesDiscovery
6LIFR
LIF receptor subunit alpha
High (0.97)100%yesDiscovery
7NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.83)100%uncertainFDA-Approved
8GPR139
G protein-coupled receptor 139
High (0.94)100%yesDiscovery
9MAOB
monoamine oxidase B
High (0.91)100%—FDA-Approved
10EPHB2
EPH receptor B2
High (0.72)100%uncertainFDA-Approved
11CHRNA7
cholinergic receptor nicotinic alpha 7 subunit
High (0.67)100%yesClinical
12IRAK4
interleukin 1 receptor associated kinase 4
High (0.67)100%yesClinical
13EGFR
epidermal growth factor receptor
Medium (0.36)73%yesFDA-Approved
14GABRE
gamma-aminobutyric acid type A receptor subunit epsilon
High (0.87)100%uncertainFDA-Approved
15FZD3
frizzled class receptor 3
High (0.79)100%yesDiscovery
16ADGRL1
adhesion G protein-coupled receptor L1
High (0.82)91%yesDiscovery
17NOTCH1
notch receptor 1
High (0.58)100%yesClinical
18HRH4
histamine receptor H4
High (0.61)100%yesClinical
19S1PR1
sphingosine-1-phosphate receptor 1
Medium (0.39)73%yesFDA-Approved
20IL18R1
interleukin 18 receptor 1
High (0.91)100%uncertainClinical
21HMGA1
high mobility group AT-hook 1
High (0.97)100%—Discovery
22SSTR2
somatostatin receptor 2
Medium (0.50)83%yesFDA-Approved
23MST1R
macrophage stimulating 1 receptor
Medium (0.44)100%yesFDA-Approved
24ITPR3
inositol 1,4,5-trisphosphate receptor type 3
High (0.73)100%yesDiscovery
25FAP
fibroblast activation protein alpha
High (0.70)100%yesClinical

Internalizing receptors in gastric cancer

Targets expressed in gastric cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

HER3 (ERBB3) · IGF1R · c-MET (MET) · CYSLTR2 · AMFR · LIFR · GPR139 · CHRNA7 · IRAK4 · EGFR · FZD3 · ADGRL1

Gastric Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in gastric cancer. Clinical precedent lowers development risk but usually means more competition:

HER3 (ERBB3) · IGF1R · c-MET (MET) · NR3C2 · MAOB · EPHB2 · CHRNA7 · IRAK4 · EGFR · GABRE · NOTCH1 · HRH4

How these gastric cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in gastric cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank gastric cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free gastric cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist gastric cancer targets for your program · 5 free analyses, no card Rank gastric cancer targets free